Results 101 to 110 of about 39,459 (248)

Persistent Vascular Collagen Accumulation Alters Hemodynamic Recovery from Chronic Hypoxia [PDF]

, 2012
Pulmonary arterial hypertension (PAH) is caused by narrowing and stiffening of the pulmonary arteries that increase pulmonary vascular impedance (PVZ). In particular, small arteries narrow and large arteries stiffen. Large pulmonary artery (PA) stiffness
Chesler, Naomi C., Hacker, Timothy A., Molthen, Robert C., Roldan-Alzate, Alejandro, Tabima, Diana M., Wang, Zhijie   +5 more
core   +2 more sources

Characterization of Pulmonary Functional Abnormalities in Systemic Sclerosis Using Xenon MRI

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Xenon MRI is increasingly used to evaluate patients with interstitial lung disease (ILD) and pulmonary hypertension (PH), both of which are common manifestations of systemic sclerosis (SSc). As such, Xe‐MRI may be suited to interrogate lung function impairment in SSc.
Dawson Shaver, Steven Haworth, Evan Graumann, Bradie Frizzell, David H. Lee, Jiwoong Choi, Chase S. Hall, Scott M. Matson, Mark Hamblin, Mario Castro, Paul S. Schmidt, Peter J. Niedbalski   +11 more
wiley   +1 more source

Esclerose sistêmica e sarcoidose Scleroderma and sarcoidosis

Revista Brasileira de Reumatologia, 2005
Os autores descrevem o caso de uma paciente com esclerose sistêmica (ES) - forma limitada - com comprometimento pulmonar tipo fibrose intersticial. Após sete anos sem acompanhamento, foram identificados gânglios mediastinais e esplenomegalia.
Fernanda Guidolin, Letícia Esmanhotto, Marilia B. Silva, Lismari Mesquita, Thelma L. Skare   +4 more
doaj   +1 more source

Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. [PDF]

, 2003
We previously showed that COL1A1 expression is up-regulated at the transcriptional level in systemic sclerosis (SSc) fibroblasts and that the CCAAT-binding factor (CBF) is involved in this increased expression.
Herrick, David J, Jimenez, Sergio A., Louneva, Natalia, Saitta, Biagio   +3 more
core   +2 more sources

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source

Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. [PDF]

, 2017
BACKGROUND: Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to
Abraham, Assandri, Assassi, Auluck, Bacher, Baron, Baron, Bodukam, Cavazzana, Chizzolini, Chizzolini, Ciechomska, Clark, Cohen, Colina, Crowell, Denton, Denton, Derk, Derynck, Emmanuel, Frech, Fynne, Gabrielli, Goldblatt, Gregersen, Gu, Hartleb, Heyt, Hinz, Hu, Hudson, Hung, Ingraham, Jimenez, Johnson, Jung, Kaburaki, Kaneko, Khanna, Khanna, Koh, Krause, Kumar, Luciano, Malandrini, Manetti, Manetti, Manetti, Marie, Marie, Marie, Marie, Marie, Matucci-Cerinic, Maurer, Miao, Milette, Murray-Lyon, Nagaraja, O'Reilly, O'Reilly, Omair, Parker, Parodi, Pattanaik, Peng, Piasecki, Poelman, Radic, Raja, Raja, Raja, Rajapakse, Reynolds, Richard, Richardson, Rigamonti, Riviere, Roulis, Russell, Sakkas, Savarino, Savarino, Shawis, Singh, Singh, Sjogren, Skare, Solis-Herruzo, Spiegel, Steen, Stern, Stumpf, Thonhofer, Thoua, Trezza, Trojanowska, Valenzuela, Varga, Veale, Vischio, Watson, Wipff, Wynn, Zheng   +105 more
core   +2 more sources

Collalysin in therapy of patients with limited scleroderma

Kazan medical journal, 1986
In the pathogenesis of scleroderma an essential role is played by intensive collagen biosynthesis, which causes the development of fibrotic-sclerotic lesions. In this connection, it is pathogenetically substantiated the use of agents, the effect of which is aimed at decreasing the synthesis and increasing the catabolism of collagen.
openaire   +1 more source

Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma

Scandinavian Journal of Rheumatology, 2011
Thyroid dysfunction in the setting of systemic sclerosis (SSc) has been described previously. We aimed to determine the prevalence of anti-thyroid antibodies (ATA) in a large SSc cohort and to ascertain whether they are associated with distinct clinical phenotypes.A total of 138 patients with SSc [46 with diffuse (dSSc) and 92 with limited scleroderma (
Danielides, S., Mavragani, C.P., Katsakoulas, I., Zintzaras, E., Drosos, A.A., Vlachoyiannopoulos, P.G., Moutsopoulos, H.M.   +6 more
openaire   +4 more sources